These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 18687475

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
    Fühlhuber V, Bick S, Kirsten A, Hahn A, Gerriets T, Tschernatsch M, Kaps M, Preissner KT, Blaes F, Altenkämper S.
    J Neuroimmunol; 2009 May 29; 210(1-2):87-91. PubMed ID: 19339060
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.
    Zar T, Tschernatsch M, Hero B, Lang B, Preissner KT, Blaes F.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e176-e179. PubMed ID: 33060390
    [Abstract] [Full Text] [Related]

  • 7. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
    Krasenbrink I, Fühlhuber V, Juhasz-Boess I, Stolz E, Hahn A, Kaps M, Hero B, Blaes F.
    Neuropediatrics; 2007 Jun 01; 38(3):114-6. PubMed ID: 17985258
    [Abstract] [Full Text] [Related]

  • 8. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
    Raffaghello L, Fuhlhuber V, Bianchi G, Conte M, Blaes F, Gambini C, Pistoia V.
    J Leukoc Biol; 2013 Jul 01; 94(1):183-91. PubMed ID: 23610147
    [Abstract] [Full Text] [Related]

  • 9. New autoantibodies in pediatric opsoclonus myoclonus syndrome.
    Kirsten A, Beck S, Fühlhuber V, Kaps M, Kreutz T, Korfei M, Schmitt S, Preissner KT, Blaes F.
    Ann N Y Acad Sci; 2007 Sep 01; 1110():256-60. PubMed ID: 17911440
    [Abstract] [Full Text] [Related]

  • 10. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.
    Ding X, Yang W, Ren Q, Hu J, Yang S, Han W, Wang J, Wang X, Wang H.
    J Neuroinflammation; 2020 Jun 16; 17(1):190. PubMed ID: 32546235
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
    Ding X, Han W, Wang J, Yang W, Chang XF, Zhu ZY, Qin H, Zhang JZ, Wang X, Wang HM.
    Pediatr Res; 2019 May 16; 85(6):885-894. PubMed ID: 30718793
    [Abstract] [Full Text] [Related]

  • 14. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom.
    Pang KK, de Sousa C, Lang B, Pike MG.
    Eur J Paediatr Neurol; 2010 Mar 16; 14(2):156-61. PubMed ID: 19423368
    [Abstract] [Full Text] [Related]

  • 15. Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome.
    Blaes F, Fühlhuber V, Preissner KT.
    Expert Rev Clin Immunol; 2007 Nov 16; 3(6):975-82. PubMed ID: 20477144
    [Abstract] [Full Text] [Related]

  • 16. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome.
    Blaes F, Fühlhuber V, Korfei M, Tschernatsch M, Behnisch W, Rostasy K, Hero B, Kaps M, Preissner KT.
    Ann Neurol; 2005 Aug 16; 58(2):313-7. PubMed ID: 15988749
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment.
    Blaes F, Dharmalingam B.
    Expert Rev Neurother; 2016 Jun 16; 16(6):641-8. PubMed ID: 27095464
    [Abstract] [Full Text] [Related]

  • 19. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome.
    Rostásy K, Wilken B, Baumann M, Müller-Deile K, Bieber I, Gärtner J, Möller P, Angelini P, Hero B.
    Neuropediatrics; 2006 Oct 16; 37(5):291-5. PubMed ID: 17236108
    [Abstract] [Full Text] [Related]

  • 20. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up.
    Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML, van Noesel MM, Hakvoort-Cammel FG, van den Heuvel-Eibrink MM.
    Pediatr Blood Cancer; 2009 Dec 16; 53(6):1048-53. PubMed ID: 19672966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.